Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1999-04-09
2000-09-26
Elliott, George C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
435 6, 435 3, 435 911, 435325, 435375, 536 231, 536 243, 536 2431, 536 245, A61K 4800, C07H 2104, C12Q 168, C12N 1585
Patent
active
061242721
ABSTRACT:
Antisense compounds, compositions and methods are provided for modulating the expression of PDK-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding PDK-1. Methods of using these compounds for modulation of PDK-1 expression and for treatment of diseases associated with expression of PDK-1 are provided.
REFERENCES:
patent: 6028173 (2000-02-01), Landes et al.
patent: 6030806 (2000-02-01), Landes et al.
Andrea D. Branch, A good antisense molecule is hard to find, TIBS, 47-48, Feb. 1998.
Trisha Gura, Antisense Has Growing Pains, Science, pp. 575-577, Oct. 1995.
Stanley Crooke, Antisense Research and Applications, Chapter 1, Basic Principles of Antisense Therapeutics, Springer-Verlag Press, Berlin, Heidelberg, New York, p. 3, Jul. 1998.
Uhlmann et al. Antisense Oligonucleotides: A New Therapeutic Principle. Chemical Reviews, vol. 90, No. 4., pp. 545-546, Jun. 1990.
Alessi et al., Mechanism of activation and function of protein kinase B, Curr. Opin. Genet. Dev., 1998, 8:55-62.
Alessi et al., 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase, Curr. Biol., 1997, 7:776-789.
Alessi et al., Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha, Curr. Biol., 1997, 7:261-269.
Anderson et al., Translocation of PDK-1 to the plasma membrane is important in allowing PDK-1 to activate protein kinase B, Curr. Biol., 1998, 8:684-691.
Cohen et al., PDK1, one of the missing links in insulin signal transduction?, FEBS Lett., 1997, 410:3-10.
Downward, Mechanisms and consequences of activation of protein kinase B/Akt, Curr. Opin. Cell Biol., 1998, 10:262-267.
Le Good et al., Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1, Science, 1998, 281:2042-2045.
Staal, Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma, Proc. Natl. Acad. Sci. U S A, 1987, 84:5034-5037.
Staal et al., The AKT1 proto-oncogene maps to human chromosome 14, band q32, Genomics, 1988, 2:96-98.
Stokoe et al., Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B, Science, 1997, 277:567-570.
Cowsert Lex M.
Monia Brett P.
Elliott George C.
Epps Janet
Isis Pharmaceutical Inc.
LandOfFree
Antisense modulation of PDK-1 expression does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antisense modulation of PDK-1 expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antisense modulation of PDK-1 expression will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2100286